Cargando…

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

OBJECTIVES: To explore the epidemiological information, clinical characteristics, therapeutic outcomes and temporal progression of laboratory findings in 2019-coronavirus disease (COVID-19) patients exposed to lopinavir. METHODS: We collected data from ten COVID-19 patients admitted between January...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Fang, Xu, Aifang, Zhang, Yan, Xuan, Weiling, Yan, Tingbo, Pan, Kenv, Yu, Wenyan, Zhang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193136/ https://www.ncbi.nlm.nih.gov/pubmed/32173576 http://dx.doi.org/10.1016/j.ijid.2020.03.013

Ejemplares similares

Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients
por: Eljaaly, Khalid, et al.
Publicado: (2020)

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
por: Osborne, Vicki, et al.
Publicado: (2020)

How COVID‐19 pandemic may hamper sustainable economic development
por: Ahmed, Maruf Yakubu, et al.
Publicado: (2021)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
por: Cao, Bin, et al.
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

Colchicine may not be effective in COVID-19 infection; it may even be harmful?
por: Cumhur Cure, Medine, et al.
Publicado: (2020)

May polyenthesitis follow COVID-19?
por: Ciaffi, Jacopo, et al.
Publicado: (2021)

Dealing with the COVID-19 pandemic: an opportunity to reflect on sustainability research: May 29 2022
por: Nölting, Benjamin, et al.
Publicado: (2022)

Liver injury in COVID-19 – The culprit may not be COVID-19!
por: Singh, Aditya, et al.
Publicado: (2021)

Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19
por: Zhang, Yan, et al.
Publicado: (2021)

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
por: Sun, Duxin
Publicado: (2020)

Teledermatology May Benefit Marginalized Populations: National and Institutional Trends during the COVID-19 Pandemic
por: Patel, Akash D., et al.
Publicado: (2023)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
por: Mas Serrano, Miguel, et al.
Publicado: (2020)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
por: Owa, Adewale Bayode, et al.
Publicado: (2020)

Comment on “Colchicine may not be effective in COVID-19 infection; it may even be harmful?”
por: Kobak, Senol
Publicado: (2020)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
por: Ye, Linhu, et al.
Publicado: (2021)

What POST-COVID-19 lifestyles may look like? Identifying scenarios and their implications for sustainability
por: Echegaray, Fabián
Publicado: (2021)

COVID-19: the worst may be yet to come
por: The Lancet
Publicado: (2020)

The ARDSnet protocol may be detrimental in COVID-19
por: Tsolaki, Vasiliki, et al.
Publicado: (2020)

COVID-19 may transmit through aerosol
por: Wang, Juan, et al.
Publicado: (2020)

Debate on drugs that may aggravate COVID-19
por: Giavina-Bianchi, Pedro, et al.
Publicado: (2020)

Ventilators may not be best for severe covid-19
por: Wilson, Clare
Publicado: (2020)

Recovery from Covid-19 may be prolonged
por: Gupta, Harish, et al.
Publicado: (2021)

Four Patients with COVID-19 and Tuberculosis, Singapore, April–May 2020
por: Tham, Sai Meng, et al.
Publicado: (2020)

Post-traumatic symptoms after COVID-19 may (or may not) reflect disease severity
por: Badenoch, James, et al.
Publicado: (2020)

Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit
por: Sun, Duxin
Publicado: (2020)

Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
por: Cunningham, Louise, et al.
Publicado: (2020)

Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients
por: Lacout, Alexis, et al.
Publicado: (2021)

New machine learning model predicts who may benefit most from COVID-19 vaccination
por: Wedlund, Leia, et al.
Publicado: (2021)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
por: Zanon, D., et al.
Publicado: (2020)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
por: Wada, Tatsuhiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k32p0m8l0fq8mnqi074av6h9ia